PDA: Drugs for Parkinson's Disease

used to treat extrapyramidal SE occuring during antipsychotic treatment, may improve depression (psychotic) and mental inertia

anticholinergic, antimuscarinic class, reduce frequency of oculogyric crises, dyskinetic movement, spastic interactions

used to treat SE occurring during antipsychotic treatment, may improve depression (psychotic) and mental inertia

SE: dry mouth, blurred vision, urine retention, CNS: drowsiness, vertigo, headache & dizziness. HIGH DOSES: delirium, nervousness, agitation

ABUSE: may be abused due to short-acting mood-elevating and euphoriant effect

may lower seizure threshold

increased dopamine synthesis, it can cross the BBB unlike dopamine, allows reduced inhibition of motor systems --> increased motor output

hypotension, arrythmias, nausea, GI bleeding, hair loss, extreme emotional states, insomnia

prevents dopamine re-uptake -> selective irreversible MAO-B inhibitor (MAO-B metabolises dopamine). SE: nausea, hallucinations, confusion,